Cardioacc closes nearly 100M yuan Series A round led by Medtronic China Fund

Shenzhen Cardioacc Technology Co., Ltd. ("Cardioacc") recently announced the completion of its Series A funding round, raising nearly 100 million RMB. This round was led by Medtronic China Fund, with continued investment from existing shareholders Yuanbio Venture Capital, Qinghe Tongxin, and Tongfang Investment. This strong support fully demonstrates the high recognition from both strategic partners and the market regarding the company's technological capabilities and sustainable growth prospects. The raised capital will be allocated toward mass production of core products, commercial expansion, and research and development of new product pipelines.

Cardioacc was established in October 2021 in Bao'an District, Shenzhen. Over the four years since its founding, Cardioacc has completed five rounds of equity financing. The company remains dedicated to developing innovative medical devices for cardiac interventional imaging with global competitiveness. Focusing on unmet clinical needs and operating within China's healthcare environment that emphasizes cost reduction and efficiency improvement, Cardioacc continuously achieves breakthroughs through its solid fundamental R&D capabilities. It provides the industry with safe, effective, and cost-controllable precision diagnostic solutions, striving to become a world-class interventional ultrasound platform company and drive future change through innovation.

Cardioacc's self-developed "Single-Use Intracardiac Echocardiography Catheter," featuring a minimal diameter of just 7.5F, obtained China Class III medical device registration certification (Registration Certificate No.: 20253060489) in March 2025. This ultrasound catheter incorporates industry-leading manufacturing techniques that significantly enhance its accessibility and maneuverability, providing critical clinical value for complex procedures and patients with small cardiac chambers (including those with congenital heart disease). Furthermore, the product utilizes an innovative self-locking handle design that enables effortless single-handed deflection control and provides neutral position indication, substantially improving the convenience and efficiency of interventional procedures.

Meanwhile, Cardioacc's self-developed four-dimensional intracardiac echocardiography system utilizes a volume-scan imaging solution based on soft beamforming synthesis. This innovative approach eliminates the need for ASIC chips and a large number of transducer array elements, significantly reducing the processing complexity and cost of consumables compared to traditional 4D intracardiac ultrasound systems. Additionally, the product features a large field of view and high volume rate, enabling real-time 4D imaging while maintaining excellent image quality.

To date, Cardioacc has secured or has pending nearly 50 patents globally, establishing a robust technological barrier. The company has not only filled a critical gap in the domestic Chinese market for intracardiac ultrasound imaging devices but has also driven advancements in related industries, including high-end imaging algorithms, micro-nano ultrasonic transducers, and precision catheter manufacturing. This progress is contributing to a broader technological revolution in minimally invasive cardiac interventional imaging. Looking ahead, Cardioacc will continue to expand its global patent portfolio and pursue international product registration, accelerating its worldwide presence while delivering even safer and more efficient device solutions to the clinical community.